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The alphaherpesvirus, equine herpesvirus type 1 (EHV-1), is a highly prevalent cause of equine infectious abortion
and encephalomyelopathy. These syndromes have been attributed to ischemic necrosis from thrombosis in
placental and neural vessels, although the mechanisms underlying thrombosis are unknown. After inhalation, EHV-1
establishes a peripheral blood mononuclear cell-associated viremia, with monocytes being a target of infection.
Monocytes are also the main source of tissue factor (TF) in diseased states. Since TF is the primary activator of
coagulation, increased monocyte TF expression could be involved in EHV-1-associated thrombosis. We
hypothesized that EHV-1 infection would induce TF-dependent procoagulant activity in equine monocytes.
Monocyte-enriched fractions of blood were infected with abortigenic (RacL11, NY03) and neuropathogenic (Ab4)
EHV-1 strains. All strains induced procoagulant activity, to variable degrees, within 1 to 4 h, with maximal activity at
24 h, after infection. Virus-induced procoagulant activity was similar to that seen with lipopolysaccharide, a known
stimulant of TF-mediated procoagulant responses. Virus-induced procoagulant activity was factor VIIa-dependent
and temporally associated with TF gene transcription, implicating TF as the main driver of the activity. Procoagulant
activity was mildly decreased (30-40%) when virus was inactivated by ultraviolet light or when infected cells were
treated with aphidicolin, a virus DNA polymerase inhibitor, suggesting early events of virus infection (attachment,
entry or intracellular trafficking) are the primary stimulus of procoagulant activity. Our results indicate that EHV-1
rapidly stimulates procoagulant activity in equine monocytes in vitro. The EHV-1-induced procoagulant activity in
monocytes may contribute to clinical thrombosis in horses with EHV-1 infection.Introduction
Equine herpesvirus type 1 (EHV-1) is a member of the
genus Varicellovirus within the Alphaherpesvirinae
subfamily and has a double stranded DNA genome. It
is highly prevalent and pathogenic in horses, causing
large-scale outbreaks of respiratory disease, abortion
storms and encephalomyelopathy [1]. Horses are exposed
to EHV-1 through aerosolization [1-2]. After primary
replication in the respiratory epithelium, the virus dissemi-
nates systemically through a peripheral blood mononuclear
cell (PBMC)-associated viremia [3-7]. The EHV-1-associ-
ated disease syndromes of abortion and encephalo-
myelopathy have been attributed to ischemic injury from
thrombosis in vessels of the placenta and the central ner-
vous system, mostly in the spinal cord, respectively [8-10].* Correspondence: ts23@cornell.edu
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can activate the hemostatic system, resulting in a
hypercoagulable state that can manifest as thrombosis or
disseminated intravascular coagulation [11-13]. Experi-
mental models have revealed that upregulation of tissue
factor (TF) expression on monocytes is the main trigger
for hypercoagulability in bacterial sepsis [14,15], however
the mechanisms underlying hemostasis activation with
virus infection are less well understood. In vitro studies
have shown that viruses can upregulate TF in infected
endothelial cells [16-18]. However, monocytes are now
considered the main source of TF in inflammatory states,
including that due to bacterial sepsis [14,19]. Far less is
known of the role of monocytes in virus-induced
hypercoagulability. Four bovine respiratory viruses
upregulated TF in alveolar macrophages in vitro [20]
while cytomegalovirus (a betaherpesvirus) and influenza
virus induced TF-dependent procoagulant activity in
human monocytes in vitro [21]. In vivo studies have. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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in hemostasis in several virus infections [22-24].
The mechanisms of thrombosis in EHV-1 infection
have not been established, although endothelial injury
certainly may be involved [3,9,10]. However, blood
monocytes are susceptible to EHV-1 infection in vitro
and in vivo [2,5,25-27] and may serve as the primary
virus transporters to endothelial cells at sites distant
from the respiratory tract [2,28,29]. Since monocytes are
also the source of induced TF expression in disease states,
we hypothesized that EHV-1 infection would induce
procoagulant activity in equine peripheral blood monocytes
in a TF-dependent manner. Monocyte-enriched fractions
from equine peripheral blood were infected with
abortigenic (RacL11, NY03) and neuropathogenic (Ab4)
strains of EHV-1. At various times after infection with live
or inactivated virus, monocyte procoagulant activity was
measured with a two-stage amidolytic activity assay, based
on the generation of activated factor X (FXa). TF mRNA
was also quantified at different times after infection and
flow cytometric analysis was performed to verify infection
of monocytes by EHV-1 and determine if EHV-1 induced
cell death in infected monocytes.
Materials and methods
Virus amplification, concentration and titration
The following EHV-1 strains were used: RacL11D752,
Ab4D752, NY03N752, Ab4D752 expressing green fluorescent
protein (Ab4D752-GFP), RacL11N752-GFP and Ab4N752-
GFP. The RacL11 strain was isolated from an aborted
fetus in the 1950s [30], whereas Ab4 was isolated from a
quadriplegic mare that had previously aborted during an
EHV-1 outbreak in 1980 [9]. NY03 is an isolate from an
aborted fetus in the state of New York in 2003 [31].
Wild-type RacL11 and Ab4 strains contain a single G to
A polymorphism in the catalytic subunit of the EHV-1
DNA polymerase at position 2554, which results in a
single amino acid substitution of aspartic acid (D) for
asparagine (N) at position 752 (D752) that was shown to
be associated with neurological disease [25,27,32,33].
The NY03 strain has a G nucleotide at this posi-
tion (N752). The mutant viruses, RacL11N752-GFP and
Ab4N752-GFP, were generated by substituting A for G, as
previously described [25]. GFP-expressing strains were
produced by substituting the GFP gene for the virus gene
71, which encodes for the nonessential glycoprotein gp2,
as previously described [34]. A clinical equine herpesvirus
type 4 (EHV-4) field isolate was kindly provided by Dr
Dubovi (Cornell University). All EHV-1 strains were
propagated in rabbit kidney cells (RK13), which were
cultured in Dulbecco’s Modification of Earl’s Medium
(Mediatech, Inc.) supplemented with L-glutamine, glucose,
sodium pyruvate and 10% fetal bovine serum (Atlanta
Biologicals, Inc.) and grown in 75 cm2 flasks (CorningInc.) at 37°C under 5% carbon dioxide. One-day-old
confluent monolayers of RK13 cells were infected with the
respective virus strains at a multiplicity of infection (MOI)
of 0.1 until a cytopathic effect of approximately 90%
was achieved. The flasks were then subjected to two
freeze-thaw cycles. The respective culture media were
centrifuged at 1800 × g for 15 min at 4°C, aliquoted,
and subjected to ultracentrifugation at 175 000 × g for
1 h at 4°C. The supernatant was removed (and stored
for later use as a negative control) and the pellet was
reconstituted with 1 mL sterile phosphate-buffered saline
(PBS, pH 7.4) and stored at −20°C. The virus titers of the
respective concentrates were determined using a standard
plaque assay.
Virus infection of monocyte-enriched and monocyte-
depleted fractions of peripheral blood mononuclear cells
Peripheral blood was collected with minimal restraint on
multiple different occasions from the jugular vein of 14
non-pregnant Thoroughbred mares ranging in age from 3
to 20 years, using a blood collection set (40 inch, MWI
Veterinary Supply). Blood was collected directly into a 250
mL evacuated container (Baxter Healthcare Corporation),
containing heparin (10 units/mL, Sigma-Aldrich). All
animal procedures were approved by the Cornell University
Institutional Animal Care and Use Committee and were
in accordance with the guidelines established by the
National Institutes of Health. Leukocyte-rich plasma was
obtained by gravity sedimentation of erythrocytes for 20
min at room temperature. The plasma was then
centrifuged at 288 × g for 10 min at 20°C. The cell pellet
was resuspended with PBS (pH 7.2), then layered onto
Histopaque 1.077 (GE Healthcare) at a ratio of 2:1 cell
suspension to Histopaque and centrifuged at 468 × g for
15 min at 20°C. The PMBC layer was removed, washed
twice in PBS, and then was resuspended in MACS buffer
(MACS, Miltenyi Biotec). The cell suspension was
incubated with a murine monoclonal anti-equine CD14
antibody (clone 105, 20 μg/mL) [35] for 15 min at 4°C.
Antibody-bound cells were positively selected by incuba-
tion with a secondary rat anti-mouse antibody conjugated
to metal beads (Miltenyl Biotec, 1:100) for 15 min at 4°C
followed by passage through a magnetic column as
recommended by the manufacturer. The sorted (mono-
cyte-enriched) and flow through (monocyte-depleted)
fractions were washed in PBS and resuspended in RPMI
medium containing 10% autologous plasma that had been
rendered free of cell-derived microparticles by two steps
of high-speed centrifugation at 21 130 × g for 30 min at
4°C. The percentage of monocytes in each fraction was
determined by performing differential cell counts on 200
leukocytes in Wright’s-stained cytospin smears prepared
from each fraction immediately after sorting. The cells
were seeded at a density of 5 × 105 cells/well in 96-well
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various EHV-1 strains at an MOI of 1 or 5 for 1 h at 37°C.
The infected cells were then washed twice with warmed
PBS to remove non-infectious virus particles and fresh
media was added. Vehicle (PBS) and lipopolysaccharide
(LPS, 10 ng/mL, Sigma-Aldrich) served as negative and
positive [36] controls, respectively. Infected and control
(uninfected) cells from the same horse were incubated
simultaneously for various times (1, 2, 4 or 24 h) in a
humidified chamber at 37°C with 5% carbon dioxide. In
some experiments, viruses were inactivated by exposure
to ultraviolet (UV) light for 20 min before infection or
infected cells were treated with the virus DNA polymerase
inhibitor, aphidicolin (10 μM, Sigma-Aldrich), which was
added after 1 h of virus adsorption.
Measurement of procoagulant activity on monocyte
surfaces
Infected and control cells (5 × 105) were washed twice
with HEPES buffer (10 mM HEPES, 137 mM sodium
chloride, 5 mM calcium chloride, 4 mM potassium
chloride, 10 mM glucose, 0.5% bovine serum albumin,
pH 7.4), then procoagulant activity was measured using
a standard two-step amidolytic assay based on FXa
generation. In brief, recombinant human activated factor
VII (FVIIa, final concentration, 1 nM, Hematologic
Technologies) and factor X (FX, final concentration, 75
nM, Hematologic Technologies) diluted in HEPES buffer
were added to the cells for 15 min at 37°C. Chromogenic
substrate (Spectrozyme-FXa, final concentration, 167
μM, American Diagnostica) was then added and the
ensuing color change was measured after 10 minutes at
an optical density of 405 nm at 37°C with a plate
spectrophotometer (Synergy 2, Biotek, Winooski, VT,
USA). Optical density results were converted to the
amount of FXa generated (nM) based on a standard curve
created from serial dilutions of human recombinant FXa
(American Diagnostica) that were incubated with the
substrate for 10 min. The standard curve was linear
between FXa concentrations of 4.69 and 0.29 nM, the
latter yielding optical densities more than twice baseline
values (infected or control cells with no exogenous FX or
chromogenic substrate). For data analysis, values above
and below the linearity of the standard curve were
standardized to 4.69 and 0 nM FXa, respectively. Human
recombinant TF (Innovin, Dade-Behring) with added
reagents was included as a positive assay control.
Quantitative real-time PCR for TF mRNA
Total RNA was isolated with the RNeasy mini kit
(Qiagen), using RNase-Free DNase, according to the
manufacturer’s protocol. Complementary DNA (cDNA)
was synthesized using Superscript III first strand reverse
transcriptase kit (Life Technologies) according to themanufacturer’s protocol. Resulting cDNA concentrations
were measured at 260 nm with a nanodrop spectropho-
tometer (NanoVue, GE Healthcare). Gene-specific and
housekeeping gene (equine β2-microglobulin) primers
were designed using the NCBI primer blast program and
the final sequences were verified against the available
mammalian genome database (NCBI/BLAST) to avoid
non-specific homology (Table 1). Quantitative PCR was
performed on 200 ng cDNA samples using PowerSybr
green in a MicroAmp Fast Optical 96-well reaction plate
(Applied Biosystems) according to the manufacturer’s
protocol. Samples were run in duplicate or triplicate on
an ABI StepOnePlus Real Time PCR system in standard
mode, with 10 min of denaturation at 95°C, followed by
40 cycles of 15 s at 95°C and 60 s at 60°C and 60 s at
72°C. Melting curve analysis was used to confirm the
presence of a single PCR product. The data were analyzed
with the ΔΔCT method [37], with results being nor-
malized to the housekeeping gene and expressed as the
log2 fold difference in target quantity between the test
sample and vehicle-treated control (set to 0).
Flow cytometric analysis of virus infectivity of monocytes
Monocyte-enriched and -depleted cultures were infected
with RacL11N752-GFP and Ab4D752-GFP at an MOI of 1
for 24 h, with vehicle (PBS) and non-GFP-expressing
virus as controls. The samples were then labeled with an
Alexa647 (A647)–conjugated murine anti–equine CD14
antibody (clone 105) or an A647-conjugated isotype
control for 15 min at 4°C and washed three times with
PBS. Then 15 000 cells/sample were analyzed on a
FACSCaliburTM flow cytometer (Becton Dickinson)
using the following settings: forward scatter (FSC): E00
voltage, 1.14 amp gain, linear mode, threshold 180; side
scatter (SSC): 434 voltage, 1.00 amp gain, linear mode;
and fluorescence on log mode. The percentage of cells
that were positive for A647-CD14 or GFP was measured
on quadrant dotplots.
Flow cytometric assessment of cell death
To determine if EHV-1 induced cell death, we infected
cells for 4 or 24 h with all EHV-1 strains at an MOI of 1
and 5 and then measured changes in mitochondrial
transmembrane potential (ΔΨm) by staining with a
fluorescent cationic dye and monitoring changes in
fluorescence with flow cytometry, according to the
manufacturer’s protocol (DePsipherTM kit, Trevigen
Inc.). For analysis, monocytes were gated based on their
FSC and SSC characteristics. In healthy cells with a high
negative ΔΨm, the lipophilic cationic dye accumulates in
the mitochondrial matrix as a multimer and fluoresces
bright red (FL2 channel). Red fluorescence is lost when the
cells have altered mitochondrial membrane permeability,
an early marker of apoptosis [38]. Since changes in ΔΨm
Table 1 Primers used for measurement of equine TF mRNA by quantitative real-time PCR
Gene Length (bp) Amplicon size Sequence (5’ – 3’)
Equus caballus TF forward 23 243 5' - GTGGCTAGAGCCGCAGGGACTAG
Equus caballus TF reverse 21 243 5' - AGGAAGAGACCCGCGCCATGT
Equus caballus β2-microglobulin forward 22 209 5’ - TGTCTCTGGGTTCCATCCGCCT
Equus caballus β2-microglobulin reverse 25 209 5’ - CGGACCCACTTAACTATCAGGGGGT
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live-dead assay by staining for Annexin V and measuring
propidium iodide uptake (TACSW Annexin V-FITC kit,
Trevigen Inc), according to the manufacturer’s protocol.
This was done on monocyte-enriched fractions infected
with RacL11 at an MOI of 1 or 5 for 4 or 24 h. Cells
treated with LPS (10 ng/mL or 10 μg/mL) and sodium
azide (25 mM, Sigma-Aldrich) served as positive
treatment and cell death controls, respectively, whereas
vehicle- (PBS) treated cells were used as a negative control
for all cell death experiments.
Statistical analysis
Data were parametric and results are expressed as
mean ± SD values. Comparison between multiple means
was performed with a 1-way ANOVA followed by a
Tukey’s Multiple Comparison Test. Comparison of two
means was performed with a paired t-test (Prism 5.0 for
Mac OS, version 5.0c, GraphPad Software Inc). Signifi-
cance was set at p < 0.05.
Results
EHV-1 infection of monocytes and induction of
procoagulant activity
To verify that monocytes were infected with EHV-1
in vitro, flow cytometric analysis with the GFP-expressing
variants RacL11N752 and Ab4D752 was done. A monocyte
purity of 81 ± 7% (range 65-88%, n = 10) was obtained in
the monocyte-enriched fraction with the anti-equine
CD14-based immunopurification technique, as assessed
by differential leukocyte counts on cytospin preparations
of the fraction. Flow cytometric analysis was performed 24
h after infection of monocyte-enriched and -depleted
fractions to allow time for virus infection and replication.
Monocytes were the predominant cell type infected with
the RacL11 strain (43.9 ± 2.2%) in both fractions (Figure 1).
Similar observations were made when the Ab4 strain was
used (data not shown), but infection rates were slightly
lower with this strain (38.4 ± 2.8%).
Monocyte-enriched and -depleted fractions were then
infected with the RacL11 strain of EHV-1 at an MOI of
5 for 4 h, using LPS (10 ng/mL) as a positive control.
This time point was initially chosen because it is close to
the peak procoagulant activity previously reported for
LPS-stimulated equine monocytes [36]. Both RacL11
infection and LPS treatment caused a significantincrease in procoagulant activity in the monocyte-
enriched fraction compared to the monocyte-depleted
fraction and vehicle-treated controls. The increase in
procoagulant activity was significantly higher after LPS
stimulation than after RacL11 infection (Table 2). The
procoagulant activity of both negative controls and
RacL11-infected or LPS-treated monocyte-depleted
fractions were below the assay detection limit. Two
other EHV-1 strains, Ab4 and NY03, also induced pro-
coagulant activity in equine monocyte-enriched fractions
after 4 h of infection, although the response was highest
with the RacL11 strain (Figure 2A). Because inhibitory
antibodies against equine TF are unavailable, controls
lacking exogenous FVIIa were used as a surrogate marker
of TF involvement in the induced procoagulant activity.
The increase in procoagulant activity after infection with
all EHV-1 strains (MOI of 1 or 5) and LPS stimulation
was abolished in the absence of exogenous FVIIa (Table 3,
only RacL11 is shown at an MOI of 1) supporting
TF-triggered, FVIIa-dependent generation of FXa.
The induced procoagulant activity was not due to
LPS contamination of purified virus because virus-free
supernatants obtained after ultracentrifugation did not
stimulate any procoagulant activity in the monocyte-
enriched fractions (data not shown). Other herpesviruses
can acquire TF from the membranes of the host cells they
are propagated in [40]. All three purified virus alone
(tested at concentrations similar to an MOI of 5)
expressed small amounts of TF that were usually below
the limit of detection of the assay (0.19 to 0.39 nM FXa),
but higher than the negative controls (virus preparations
with no added FX or substrate). The amount of FXa
generated by the virus alone was far lower than that
induced by virus infection or LPS stimulation of cells. This
data suggests that EHV-1, similar to other herpesviruses,
do acquire TF from the propagating rabbit kidney cellular
membranes, but the small amount of procoagulant activity
on the purified virus is insufficient to account for the
observed activity in infected equine monocytes.
Time course of EHV-1 induction of procoagulant activity
and TF mRNA expression in equine monocytes
Procoagulant activity was measured in monocyte-enriched
fractions at 1, 2, 4 and 24 h after infection with all 3 virus
strains at an MOI of 1 or 5 in different experiments. At an
MOI of 1, procoagulant activity was evident at 4 h after
AB
Figure 1 EHV-1 preferentially infects equine monocytes in peripheral blood mononuclear cells. Monocytes were enriched from equine
PBMC using an anti-equine CD14 antibody and immunomagnetic beads. Monocyte-enriched (A, left panel) and -depleted (A, right panel)
fractions of PBMC (5 × 105 cells) were infected for 24 h with RacL11N752-GFP (MOI of 1), then labeled with an A647-conjugated anti-CD14
antibody, after which 15 000 cells were analyzed for EHV-1 infection (GFP-positivity) by flow cytometry. Mock-infected monocyte-enriched
fractions labeled with an A647-isotype antibody (B, left panel) or A647-conjugated anti-CD14 antibody (B, right panel) served as negative controls,
with the isotype control being used to define the quadrants. Numbers in each quadrant represent percentage of total events. The majority of
GFP-positive cells (upper and lower right quadrants) in EHV-1-infected monocyte-enriched and -depleted fractions are CD14-positive monocytes
(upper right quadrant).
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earlier time points of EHV-1 infection and in all vehicle
treated controls was below the assay detection limit
(Figure 2A, left panel). In contrast, at an MOI of 5,
procoagulant activity was observed as soon as 1 h after
virus infection and was significantly higher with all
three virus strains compared to vehicle negative and
LPS positive controls at this time point (Figure 2A, right
panel). Furthermore, the induced procoagulant activity
was higher at an MOI of 5 compared to an MOI of 1 at
all time points with all virus strains (Figure 2A, left versus
right panel). Procoagulant activity was maximal 24 h after
infection at both MOI or LPS stimulation. RacL11 consist-
ently induced the highest procoagulant activity of all virusstrains (Figure 2A). Basal procoagulant activity and the
degree of change in procoagulant activity varied between
individual horses and experiments. Similar variability in
basal and stimulated procoagulant activity is a recognized
phenomenon with human monocytes [41].
To determine if the induction of procoagulant activity
due to EHV-1 was associated with TF gene transcription,
quantitative real-time PCR was performed at 1, 4 and 24
h after EHV-1 infection at an MOI of 1 and 5 or LPS
stimulation. An increase in TF mRNA expression
occurred within 1 h of infection with RacL11 at both
MOI, which paralleled the TF mRNA response to LPS
(Figure 2B). Similar to changes in procoagulant activity,
there was a greater relative increase in TF mRNA
Table 2 EHV-1 induces procoagulant activity primarily in
the monocyte-enriched fraction of equine peripheral
blood mononuclear cells
Treatment Vehicle RacL11 LPS
Monocyte-enriched* 0 2.36 ± 0.05** 2.78 ± 0.07**
Monocyte-depleted 0 0 0
Monocytes were purified using a murine anti-equine CD14 antibody and
procoagulant activity was measured in monocyte-enriched and -depleted PBMC
fractions with a two-stage amidolytic assay 4 h after infection with RacL11 (MOI
of 5), using LPS (10 ng/mL) positive and vehicle (PBS) negative controls. Data
represents the mean ± SD of FXa generation (nM) from 3 horses.
* p < 0.05 comparing all treatments for monocyte-enriched cells.
** p < 0.05 versus the monocyte-depleted fraction.
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points (Figure 2B, left versus right panel). The
upregulated mRNA expression peaked at 4 h (preceding
the peak procoagulant activity), then began to return to
baseline levels at 24 h after infection or stimulationA
B
Figure 2 Time course of procoagulant activity and mRNA expression
fractions of equine PBMC (5 × 105 cells) were infected with the RacL11, Ab
panel, n = 10) or treated with LPS (10 ng/mL) positive or vehicle (PBS) neg
after infection. FXa generation was below the limit of detection at all time
viruses at an MOI of 1 and are subsequently not shown in the left panel. T
treated with LPS is significantly different than the vehicle control (p < 0.05)
infection with all virus strains at an MOI of 1 (left panel) and 1 h after treat
are derived from different horses and experiments. * p < 0.05 versus other
point. ** p < 0.05 versus Ab4 or NY03 only. † p < 0.05 versus NY03 only. B:
monocyte-enriched PBMC fractions infected with RacL11 at an MOI of 1 (le
(PBS) controls. The data is expressed as the mean ± SD log2 fold increase i
(standardized to 0) after normalization to the housekeeping gene, β2-micro(Figure 2B). Similar results were observed with the Ab4
and NY03 EHV-1 strains at an MOI of 5 (data not shown).Effect of the D752 polymorphism in the virus DNA
polymerase on EHV-1-induced procoagulant activity
The RacL11 -and Ab4 EHV-1 strains both contain the
D752 polymorphism, which has been associated with
neurovirulence [25,27,32,33], whereas the NY03 strain has
the N752 polymorphism in the virus DNA polymerase.
The observation that all 3 EHV-1 strains induced
procoagulant activity in equine monocytes, albeit to
different degrees (Figure 2), argues against a major
role for this known pathogenic polymorphism in the
induction of procoagulant activity. To more directly
determine the effect of this polymorphism on procoagu-
lant activity, monocyte-enriched fractions were infected
with wild type EHV-1 RacL11D752 and Ab4D752 andafter EHV-1 infection of equine monocytes. A: Monocyte-enriched
4 or NY03 strains of EHV-1 at an MOI of 1 (left panel, n = 4) or 5 (right
ative controls. Procoagulant activity was measured at 1, 2, 4 and 24 h
points for the vehicle control and at 1 and 2 h after infection for all
he mean procoagulant activity of cells infected with all viruses or
at all time points, with the following exceptions: 1 or 2 h after
ment with LPS (both panels). Note, results depicted in the two panels
virus strains (for RacL11) or all virus strains (for LPS) at the same time
Time course of quantitative real-time PCR analysis for TF mRNA in
ft panel) or 5 (right panel) or treated with LPS (10 ng/mL) and vehicle
n TF mRNA expression relative to the vehicle-treated control at 1 h
globulin (n = 3–6).
Table 3 EHV-1- and LPS-induced procoagulant activity is
FVIIa-dependent
Treatment Vehicle RacL11 LPS
FVIIa 0 1.97 ± 0.27* 2.89 ± 0.37*
No FVIIa 0 0 0
Procoagulant activity (mean ± SD FXa generation in nM) was measured with
and without exogenous FVIIa in monocyte-enriched PBMC fractions 4 h after
infection with RacL11 (MOI of 1) or treatment with LPS (10 ng/mL) or vehicle
(PBS) (n = 3).
* p < 0.05 versus no FVIIa.
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Ab4N752). Both parental and mutant viruses induced
procoagulant activity in monocytes, although the degree
of induction was significantly lower with the N752 mutant
of RacL11 only (Table 4).
Effect of virus inactivation and EHV-4 infection on
monocyte procoagulant activity
To determine if procoagulant activity was induced by
early or immediate early (pre-replication) phases of virus
infection (attachment, entry or intracellular trafficking)
in monocytes, RacL11 was inactivated by exposure to
UV light; UV-exposed virus can presumably attach, enter
and traffic to the nucleus of cells but is incapable of
replication, which was confirmed through virus plaque
assays (data not shown). Procoagulant activity was signifi-
cantly decreased by 29 ± 5% at 4 h of infection when
UV-inactivated RacL11 was used at an MOI of 5
(Figure 3A). Similarly, mild decreases in procoagulant
activity were observed when monocytes were infected
with UV-inactivated Ab4 (31 ± 1% decrease) and NY03
(35 ± 1% decrease). The data suggested that procoagulant
activity is mainly induced by events in the early phases of
virus infection, but that synthesis of late virus proteins with
virus replication contributes to and maximizes the activity.
To test this hypothesis, we treated monocytes with the
virus DNA polymerase inhibitor, aphidicolin (10 μM) [42],
during RacL11 infection. Treatment with aphidicolin
decreased the procoagulant activity induced by RacL11Table 4 Effect of the D752 polymorphism in the virus DNA
polymerase on EHV-1-induced procoagulant activity
Infection FXa generation (nM)
None (vehicle) 0
RacL11D752 2.24 ± 0.18*
RacL11N752 1.71 ± 0.02
Ab4D752 1.85 ± 0.10
Ab4N752 1.78 ± 0.08
Monocyte-enriched PBMC fractions were infected with wild type RacL11D752
and Ab4D752 strains and engineered mutant strains (RacL11N752, Ab4N752) at an
MOI of 5. Procoagulant activity was measured at 4 h after infection or vehicle
(PBS) treatment (n = 4).
* p < 0.05 versus mutant strain. All EHV-1 infected cells had significantly
higher mean procoagulant activity than vehicle-treated cells.infection to a similar extent as UV inactivation
(aphidicolin: 29 ± 3%; UV inactivation: 35 ± 5%)
(Figure 3B). Similar decreases in procoagulant activity
were observed in monocytes treated with aphidicolin and
infected with Ab4 (25 ± 16% decrease) and NY03 (40 ±
4% decrease). However, the drug had no effect on basal or
LPS-stimulated procoagulant activity (Figure 3B). The data
indicated that synthesis of late virus proteins contributes
to the observed procoagulant activity in EHV-1-infected
monocytes. Since most of the procoagulant activity was in-
duced by pre-replication stages of virus infection, we
sought to determine if the procoagulant response was
specific to EHV-1 or could be induced by a related
herpesvirus. We thus infected monocytes with EHV-4
at an MOI of 5. We chose EHV-4 because this virus does
infect PBMC [43] and mononuclear cells in nasal explants
[44] in vitro but is not associated with thrombosis in vivo.
We found that EHV-4 did induce procoagulant activity in
equine monocytes and that this activity was also
dependent on exogenous FVIIa (data not shown), however
the response was significantly lower than that observed
with EHV-1 and was similar to that seen with UV-
inactivated EHV-1. Furthermore, unlike EHV-1, the
EHV-4-induced procoagulant response was unaffected by
UV inactivation (Figure 3A) or aphidicolin treatment (data
not shown). We concluded from the data that only the
early phases of EHV-4 infection induce procoagulant
activity and that EHV-4 replication does not contribute to
the phenomenon.Monocyte cell death after EHV-1 infection
To determine if the induced monocyte procoagulant
activity was due to a secondary effect of virus-induced cell
death, as reported for LPS-stimulated human monocytes
[45], flow cytometric measurement of mitochondrial
transmembrane potential (ΔΨm) was performed in
EHV-1-infected monocyte-enriched fractions at 4 and
24 h after infection. Disruption of ΔΨm is an early and
necessary event of apoptosis [38,39]. ΔΨm in gated
monocytes did not change after 4 h of infection with all
virus strains, regardless of the MOI used (Figure 4A and B
left panel, only RacL11 shown), or with LPS stimulation
(data not shown), in spite of pronounced increases in
procoagulant activity at this time point (Figure 2A). At
24 h after infection, mild changes in ΔΨm were seen with
all EHV-1 strains at an MOI of 1 (Figure 4A right panel,
only RacL11 shown) but changes were minimal after LPS
stimulation (Figure 4C, right panel). Marked changes in
ΔΨm were seen 24 h after infection with all virus strains
at an MOI of 5 (Figure 4B right panel, only RacL11
shown). Marked changes in ΔΨm were also seen at both
time points with the sodium azide positive control
(Figure 4C left panel, only 4 h shown).
A B
Figure 3 Inactivation of virus with UV light or aphidicolin treatment decreases EHV-1-induced monocyte procoagulant activity. A: UV
light inactivation decreases procoagulant activity induced with the RacL11 strain of EHV-1, whereas it has no effect on procoagulant activity
induced by EHV-4 (n = 3). * p < 0.05 versus vehicle negative control. ** p < 0.05 versus EHV-4-infected cells (active or inactivated). B: Aphidicolin
(10 μM) decreases the procoagulant activity induced by the RacL11 strain of EHV-1, but has no effect on basal procoagulant activity or that
induced by LPS (10 ng/mL) (n = 3). The degree of inhibition of procoagulant activity with UV light inactivation and aphidicolin are similar. Note,
results depicted in Figure 3A and B are derived from different horses. * p < 0.05 versus untreated or drug-treated vehicle (PBS) control. ** p < 0.05
versus UV light-exposed or aphidicolin-treated virus.
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we determined the percentage of dead cells (based on
Annexin V staining and/or propidium iodide uptake).
Monocytes were gated on their characteristic FSC and
SSC (R1) after infection with RacL11 at an MOI of 1 or
5 for 4 or 24 h or treatment with vehicle (PBS), LPS (10
μg/mL) or sodium azide (Figure 5, Table 5). We found
that a similar percentage of monocytes were reactive
with Annexin V or exhibited propidium iodide uptake
after EHV-1 infection at both MOI or after treatment
with PBS or LPS at both time points (Figure 5, Table 5,
only 24 h shown). A significantly higher proportion of
gated monocytes were dead at 24 versus 4 h (19.3 ± 7.6%
versus 9.5 ± 5.8%, p = 0.003, data of all treatments
combined for each time point). Also, the total percentage
of events within the monocyte gate (R1) was not signifi-
cantly different between treatments at either time point.
In contrast, there were fewer total events and more dead
cells in the monocyte gate after sodium azide treatment at
both time points (Table 5, only 24 h time point shown).
We noticed that, after in vitro culture, there was an
additional event population with similar SSC but lower
FSC compared to monocytes (Figure 5, R2) that was absent
in monocyte-enriched fractions evaluated immediately
after purification (data not shown). A similar population of
cells has been observed in LPS and calcium ionophore-
stimulated human monocytes and corresponds to dead
cells on live-dead staining [46]. We found that this
additional population was, indeed, comprised of dead
cells, regardless of infection or treatment (Figure 5,
Table 5). Furthermore, the percentage of events within
this gate was similar with all treatments at both time
points, except for sodium azide, which had, on average,
double the total events (Table 5). This increase in totalevents in the “dead cell” or R2 gate with sodium azide
corresponded to the reduction of total events in the
monocyte or R1 gate, implying the increased total R2
events after sodium azide treatment represented dead
monocytes (originally in the R1 gate). We also tested if
procoagulant activity was induced in cells treated with
sodium azide and found no significant increase in
procoagulant activity (data not shown). We concluded
from the results that the increase in procoagulant activity
in EHV-1-infected monocytes at 24 h after infection is
unlikely due to overt apoptotic cell death.
Discussion
For the first time, this study shows that EHV-1 infection
of equine monocytes induces procoagulant activity that is
mediated by increased TF gene expression and availability.
The data also suggests that virus-induced procoagulant
activity is a two-step process: initial virus binding or
uptake induces most of the activity, but virus replication is
required for maximal activity. There is also a dose-related
response, with higher infectious doses yielding higher
procoagulant activity.
The increased monocyte procoagulant activity after virus
infection was temporally and quantitatively associated with
TF mRNA expression and dependent on addition of
exogenous FVIIa. Similar findings were seen with LPS
stimulation. This indicates that TF is the main driver of
the observed activity and activity is mostly mediated
through TF gene transcription with subsequent protein
expression on monocyte surfaces, as reported for LPS
stimulation [47]. The signaling events by which EHV-1
stimulates TF mRNA production are currently unknown,
but the virus could trigger the same pathways that result
in TF gene expression after LPS stimulation, including
AB
C
Figure 4 Changes in mitochondrial membrane potential (ΔΨm) after EHV-1 infection. Monocyte-enriched fractions of equine PBMC
(5 × 105 cells) were infected for 4 (left panel) or 24 h (right panel) with the RacL11 strain of EHV-1 at an MOI of 1 (A) or 5 (B). Positive apoptosis
and stimulation controls were sodium azide (25 mM) and LPS (10 ng/mL), respectively (C, only one time point for each control shown), whereas
mock-infected cells served as a negative control (green overlay). Changes in ΔΨm were evaluated with DePsipherTM and flow cytometry. With
this technique, decreased red fluorescence (FL2) indicates altered ΔΨm, an early marker of apoptosis. Data shown is representative of 3 different
experiments. Marked changes in ΔΨm, indicative of apoptosis, were evident in cells infected with RacL11 at an MOI of 5 after 24 h and sodium
azide controls, but not in cells infected with RacL11 for 4 h at either MOI or 24 h after EHV-1 infection with an MOI of 1 or treatment of cells
with LPS.
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NFκβ, activating protein-1 or early growth response
protein-1, all of which were shown to bind to responsive
elements in the TF gene promoter and activate transcrip-
tion [48,49]. Further studies, however, are necessary to
uncover the signaling pathways by which TF mRNA is
upregulated after EHV-1 infection. At higher infectious
doses of EHV-1, procoagulant activity was observed inmonocytes within 1 h of infection and was even higher
than that seen with LPS. This rapid increase in activity
cannot entirely be attributed to de novo TF protein
synthesis and it is possible that EHV-1 induces release of
intracellular stores of TF or decrypts surface-expressed TF
[50,51]. The majority of cellular TF is stored intracellularly
within endosomes and Golgi vesicles, but studies in human
monocytes and fibroblasts have shown that these stores
Figure 5 Live-dead assay on EHV-1-infected or control-treated monocyte-enriched fractions of peripheral blood. Representative flow
cytometric analysis of Annexin V and propidium iodide staining of monocyte-enriched fractions of equine PBMC (5 × 105 cells) infected for 24 h
with RacL11 (MOI of 5, right panel). Vehicle (PBS, left panel) and LPS (10 μg/mL, middle panel) served as negative and positive stimulation
controls, respectively. Monocytes were identified and gated (R1) by their characteristic FSC and SSC. A second population of cells with lower FSC
and similar SSC was identified and similarly gated (R2; upper panel). The percentage of dead cells in each gate was determined by combining
the total percentage of cells positive for Annexin V (lower right quadrant), propidium iodide (upper left quadrant) or both Annexin V and
propidium iodide (upper right quadrant) in fluorescence dotplots (lower two panels). In this representative experiment (of n = 4), the degree of
cell death in the monocyte gate was similar for EHV-1-infected (15%), PBS- (19%) or LPS-treated (13%) cells. The R2 gate consisted mostly of dead
cells (EHV-1: 98%; PBS: 98%, LPS: 94%).
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including LPS [41,50].
We found that higher infectious doses of EHV-1
resulted in permeable mitochondrial membranes in
equine monocytes 24 h after infection, but this was not
concurrently associated with overt cell death. There are
several potential explanations for these findings. It ispossible that the cell death sequence is initiated at 24 h
and would only fully manifest at a later time. In support of
this explanation, we have observed that many monocytes
are lysed 48 h after EHV-1 infection (MOI of 5; data not
shown). Mitochondrial membrane changes are potentially
reversible [39], but this has not been reported following
virus infection. Herpesviruses can upregulate anti-
Table 5 In vitro culture of monocytes induces cell death,
which is not increased by EHV-1 infection
Treatment Monocyte gate Dead cell gate
% total % dead % total % dead
Vehicle 54 ± 21 16 ± 3 9 ± 7 65 ± 29
LPS 55 ± 25 18 ± 15 6 ± 4 80 ± 18
RacL11 MOI 1 59 ± 17 14 ± 8 9 ± 7 79 ± 24
RacL11 MOI 5 59 ± 14 16 ± 10 7 ± 5 83 ± 17
Sodium azide 33 ± 26 31 ± 26 18 ± 19 92 ± 10
Live-dead assays with Annexin V and propidium iodide were performed on
suspended monocyte-enriched fractions 24 h after EHV-1 infection with
RacL11 (MOI of 1 and 5) or treatment with LPS (10 μg/mL) or vehicle (PBS).
Sodium azide (25 mM) was used as a positive control for induction of cell
death. The mean ± SD percentage of total cells and dead cells (expressing
Annexin V or propidium iodide) was calculated in the monocyte and “dead
cell” gate (R1 and R2 in Figure 5, respectively) (n = 4). Mean percentages for
infected or treated cells were not significantly different from vehicle-treated
controls (p > 0.05).
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despite mitochondrial disruption [52]. Since the degree of
overt cell death was similar between EHV-1-infected,
mock-infected or LPS-stimulated equine monocytes and
procoagulant activity was not increased in sodium
azide-treated monocytes despite substantial cell death,
we could not attribute the increased procoagulant activity
at 24 h after EHV-1 infection to cell death. Our results
also indicate that cultured equine monocytes undergo
spontaneous cell death, which increases from 4 to 24 h of
culture, but was not enhanced by virus infection or LPS
stimulation (10 ng/mL or 10 μg/mL). Such spontaneous
cell death has also been observed in human monocytes
cultured in vitro [53,54]. Our results with LPS-treated
equine monocytes differ from that previously reported
with human monocytes, in which a lower dose of LPS
(1 μg/mL) induced more cell death than was observed in
untreated controls [45]. This could be due to species
differences in the response to LPS. The procoagulant
response after LPS stimulation was also highest at 24 h
versus 4–6 h after treatment, as reported previously for
horse monocytes [36]. The latter conflicting results may
be explained by different experimental methods, since
a two-stage amidolytic assay was used to measure
procoagulant activity on the surface of living cells in
this study whereas a clotting assay was used to measure
procoagulant activity in whole cell lysates of equine mono-
cytes in the previous study [36].
The data also revealed strain-dependent differences in
generation of procoagulant activity in equine monocytes,
with RacL11 consistently eliciting a stronger response
than Ab4 or NY03. These strain-dependent differences
were not attributable to the D752 polymorphism in the
DNA polymerase. This polymorphism has been strongly
associated with neuropathogenicity [25,27,32,33], possibly
due to a leukocyte-associated viremia of higher magnitudeand longer duration [25,27] or more efficient infection of
CD172-positive mononuclear cells after invasion through
the respiratory mucosa [2,29,44]. Interestingly, the D752
polymorphism in the virus DNA polymerase did affect the
maximal procoagulant response induced by RacL11 but
not by Ab4. The reason for this is unclear but it is unlikely
to be due to virus yields or differences in replication, since
previous studies have shown that strains harboring the
D752 or N752 polymorphism yield similar amounts of virus
[25,26]. The result does, however, support our findings
with UV-inactivated or aphidicolin-treated virus showing
that virus replication contributes to procoagulant activity
with EHV-1. The reason for the higher procoagulant
activity with RacL11 is unknown, but similar results have
been reported for chemokine gene expression patterns,
with RacL11 causing higher levels of CCL2 and CCL3
mRNA in equine PBMC than NY03 or Ab4 after 24 h of
infection [55]. Since the observed differences in infection
efficiency between RacL11 and Ab4 were small in this
study, other factors are likely causative, such as variations
in gene products between the virus strains used. The rapid
induction of procoagulant activity and TF mRNA
transcription suggests that early events in virus infection,
such as attachment, entry, intracellular trafficking or
transcription of immediate-early genes [56], may be me-
diating the observed procoagulant responses. RacL11
differs from the other two strains by partial or complete
deletions in open reading frames 1 and 2, that encode
early gene products, and also has a large deletion in the
early gene product, ICPO, a powerful transcriptional
transactivator [57]. To the authors’ knowledge, there are
no EHV-1 strain differences in the gC envelope glycopro-
tein, which facilitates herpes simplex virus-induced
procoagulant responses in human umbilical vein endo-
thelial cells [58]. Future studies are required to elucidate
which virus gene(s) are responsible for strain-dependent
differences in procoagulant activity in equine monocytes.
Procoagulant activity was induced after addition of
EHV-1 or EHV-4 to monocyte-enriched fractions. The
effect was partly replication-dependent in the case of
EHV-1, but not with EHV-4, as shown by inhibition with
UV light inactivation of the virus and aphidicolin treatment
of infected cells. EHV-4 does not appear to efficiently rep-
licate in monocytes [43,44], which may explain the lack of
replication-dependent procoagulant activity with this
virus. However, since procoagulant activity independent of
virus replication was seen with both viruses, early events
such as virus attachment, entry or intracellular trafficking,
appear sufficient to induce this response and may even be
required for the maximal procoagulant activity that is
induced by replication with EHV-1. Similar results have
been reported with endothelial cell infection by herpes
simplex virus and avian hemangioma retrovirus [59,60]. It
is possible that the procoagulant response in monocytes is
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infection. There is a mounting body of evidence that
coagulation factors, including TF, can stimulate inflam-
matory and immune responses, through cleavage of
protease-activated receptors (PARs) [61,62]. Interactions
of EHV-1 glycoproteins with cell surface receptors or
recognition of CpG-rich virus DNA by intracellular
Toll-like receptors or cytosolic DNA-dependent RNA poly-
merase following virus binding and uptake may activate
signaling pathways resulting in TF gene transcription and
other immune responses, such as chemokine secretion
[63,64]. The virus could also co-opt both innate immune
receptors and the hemostatic system to support its own
replication. For instance, both TF and thrombin, through
activation of PAR2 and PAR1 respectively, increase the
susceptibility of human umbilical vein endothelial cells to
herpes simplex virus infection [65,66].
There is some controversy over which mononuclear
cell in peripheral blood is responsible for the PBMC-
associated viremia seen after EHV-1 infection. The
cytotoxic T lymphocyte has been implicated as the
main cell responsible for both EHV-1 latency and viremia
after in vivo infection [5,67]. However, this study and
others have shown that the virus is predominantly found
in monocytes and B lymphocytes after in vitro infection of
PBMC [25,26]. Furthermore, in vivo and in vitro studies
with equine nasal explants suggest that the main targets of
infection after uptake and replication within the nasal
mucosa are CD172-positive mononuclear cells, which are
either monocytes, dendritic cells or neutrophils [2,29,44].
It is possible that monocytes are the vehicle of virus
transfer to endothelial cells in the placenta and central
nervous system [3,6,7]. In support of this, EHV-1 virus gene
products have been amplified from monocyte-enriched
fractions of peripheral blood after in vivo infection [5].
Since TF triggers the initiation phase of coagulation
in vivo, its induced expression on monocytes could
contribute to the pathologic thrombosis associated with
EHV-1 infection. However, systemic vascular thrombosis
is not a typical finding in EHV-1-infected horses; rather,
thrombosis has been observed in specific vascular beds,
including arterioles of the nasal mucosa (after aerosol
challenge), arterioles, venules and capillaries in the spinal
cord and brain, and arterioles in the placenta [8-10].
These observations indicate that monocyte-associated
TF is unlikely to be the sole cause of thrombosis in
EHV-1-infected horses and other factors are in-
volved. These factors could include, but are not limited
to, upregulation of vascular bed-specific adhesion mole-
cules, which mediate adhesion of TF-bearing monocytes
to regional endothelial cells [6,7], high regional expression
of procoagulant factors in infected monocytes and
endothelial cells [16,17], and downregulated local
anticoagulant defenses [16].Collectively, our results show that various strains of
EHV-1 induce procoagulant activity in equine monocytes
as early as 1 h after infection. The procoagulant activity
could contribute to the thrombosis observed in EHV-1-
associated disease syndromes in horses, but could also be
a mechanism by which the virus co-opts host responses to
facilitate replication and dissemination in the animal.
Since procoagulant activity does not require virus replica-
tion and also occurs with other herpesviruses that are not
associated with thrombosis in vivo, it is also possible that
the induced procoagulant activity in this inflammatory cell
may be a natural component of the host defense against
the virus. Elucidating the virus proteins and specific
signaling pathways through which EHV-1 induces pro-
coagulant responses in monocytes could provide valuable
insight into general mechanisms of how viruses affect the
innate immune response and co-opt the hemostatic
system of an infected host.
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